Belite Bio Past Earnings Performance
Past criteria checks 0/6
Belite Bio's earnings have been declining at an average annual rate of -50.1%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually.
Key information
-50.1%
Earnings growth rate
-12.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -29.4% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow
Sep 26
Are Investors Undervaluing Belite Bio, Inc (NASDAQ:BLTE) By 45%?
Jul 03We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely
Mar 20An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued
Jan 10Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price
Jul 31We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn
May 03Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate
Oct 03Belite Bio receives approval of begin LBS-008 phase 3 trial in China
Sep 16Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.
Aug 22Belite Bio GAAP EPS of -$0.23 beats by $0.05
Aug 12Belite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans
Aug 01Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment
Jul 19Revenue & Expenses Breakdown
How Belite Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -33 | 8 | 28 |
| 30 Jun 24 | 0 | -35 | 7 | 29 |
| 31 Mar 24 | 0 | -33 | 7 | 26 |
| 31 Dec 23 | 0 | -32 | 7 | 25 |
| 30 Sep 23 | 0 | -31 | 6 | 25 |
| 30 Jun 23 | 0 | -23 | 5 | 18 |
| 31 Mar 23 | 0 | -18 | 5 | 14 |
| 31 Dec 22 | 0 | -13 | 4 | 9 |
| 30 Sep 22 | 0 | -8 | 3 | 6 |
| 30 Jun 22 | 0 | -8 | 2 | 6 |
| 31 Mar 22 | 0 | -8 | 2 | 6 |
| 31 Dec 21 | 0 | -10 | 2 | 7 |
| 30 Sep 21 | 0 | -9 | 2 | 7 |
| 30 Jun 21 | 0 | -8 | 2 | 6 |
| 31 Mar 21 | 0 | -7 | 2 | 5 |
Quality Earnings: BLTE is currently unprofitable.
Growing Profit Margin: BLTE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BLTE is unprofitable, and losses have increased over the past 5 years at a rate of 50.1% per year.
Accelerating Growth: Unable to compare BLTE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BLTE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: BLTE has a negative Return on Equity (-29.44%), as it is currently unprofitable.